NCT04674735View on ClinicalTrials.gov

Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

June 30, 2025

Conditions
Meniere DiseaseVertigoVertigo Vestibular
Interventions
DRUG

APSLXR

Oral coated tablets once a day for 60 days.

Sponsors
All Listed Sponsors
lead

Apsen Farmaceutica S.A.

INDUSTRY